By John Droz, Jr., M.S. | The Defender | March 7, 2022 The U.S. Food and Drug Administration (FDA) in December 2021 granted Emergency Use Authorization (EUA) to two COVID-19 early treatment oral drugs: Pfizer’s Paxlovid and Merck’s molnupiravir. This was a major milestone, as until then, there were no FDA-endorsed pharmaceutical pill options for people diagnosed with COVID-19. The standard […]
Source